Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $589000.0.

  • Immunome's Depreciation & Amortization (CF) rose 4330.9% to $589000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 7696.41%. This contributed to the annual value of $1.6 million for FY2024, which is 22000.0% up from last year.
  • Latest data reveals that Immunome reported Depreciation & Amortization (CF) of $589000.0 as of Q3 2025, which was up 4330.9% from $637000.0 recorded in Q2 2025.
  • In the past 5 years, Immunome's Depreciation & Amortization (CF) registered a high of $637000.0 during Q2 2025, and its lowest value of $94000.0 during Q1 2023.
  • Over the past 3 years, Immunome's median Depreciation & Amortization (CF) value was $411000.0 (recorded in 2024), while the average stood at $357909.1.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 44356.44% in 2024, then soared by 1602.91% in 2025.
  • Over the past 3 years, Immunome's Depreciation & Amortization (CF) (Quarter) stood at $194000.0 in 2023, then soared by 148.97% to $483000.0 in 2024, then increased by 21.95% to $589000.0 in 2025.
  • Its last three reported values are $589000.0 in Q3 2025, $637000.0 for Q2 2025, and $611000.0 during Q1 2025.